Mirvie is a South San Francisco biotech using cell-free RNA signatures and machine learning to predict pregnancy complications - preeclampsia, preterm birth, fetal growth restriction - months before symptoms appear. Its flagship product Encompass is a blood test built on a foundational study of nearly 11,000 pregnancies.
ArteraAI is a precision medicine company building multimodal AI tests that personalize cancer therapy. Its flagship ArteraAI Prostate Test is the first AI-enabled predictive and prognostic biomarker recommended in the NCCN Guidelines for localized prostate cancer, validated across five Phase 3 trials.